9 мая 2023 г. · In all patients with EGPA, we strongly recommend tapering of glucocorticoids to the minimum effective dosage in order to reduce long-term ...

Objective To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA). Methods Patients with vasculitis or ...

9 мая 2023 г. · Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023 Jun;19(6): ...

23 сент. 2024 г. · Guidelines Summary. A European guideline on diagnosis and management of eosinophilic granulomatosis with polyangiitis (EGPA), published in 2023 ...

For remission maintenance of GPA/MPA, we recommend rituximab. In patients with relapsing or refractory eosinophilic GPA, we recommend the use of mepolizumab.

To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA).

Recommendation: For patients with active, nonsevere EGPA, we conditionally recommend initiating treatment with mepolizumab and glucocorticoids over methotrexate ...

GRADE guidelines: 14. Going from evidence to ... Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss).

1 июн. 2023 г. · We present evidence-based, cross-discipline guidelines for the diagnosis and management of EGPA that reflect the substantial advances that have been made in ...

Conventional treatment of EGPA relies on systemic glucocorticoids (GCs) in combination with cyclophosphamide when poor prognostic factors are present; however, ...